DiagnoCure (Quebec City) reported that results of a new study presented during the American Society of Clinical Oncology (ASCO; Alexandria, Virginia) meeting in Chicago provides strong evidence that its Guanylyl cyclase C (GCC) assay is able to predict colon cancer recurrence. The study was presented by Daniel Sargent, PhD, professor of biostatistics and oncology at Mayo Clinic (Rochester, Minnesota) and colleagues.